Last updated: September 2026. Editorial Team — researched using reporting from MDDI Online, Basenor, 3zebras, and Tech4Impact Summit’s strategic overview of the BCI industry. See “Sources & Methodology” for our full source list.
Quick Answer
Neuralink has moved from a single-patient research curiosity to a genuine, if still small-scale, clinical program. As of September 2025, 12 patients worldwide with severe paralysis had received the company’s brain-computer interface implant, and Musk has said the company will move to high-volume production and largely automated surgery in 2026. A significant surgical innovation — threads now passing through the brain’s protective dura membrane without needing to remove it — is described internally as a major step toward reducing invasiveness. Competing approaches from Synchron, Precision Neuroscience, and others mean Neuralink is no longer the only credible player in the field. No BCI of any kind is commercially available in 2026; every current implant operates under a research or expanded-access protocol, not as a purchasable medical product.
Where the Patient Count Actually Stands
Precisely tracking Neuralink’s patient count requires care, since different sources report figures from slightly different points in time. MDDI Online’s January 2026 reporting cites 12 patients as of September 2025. A separate August 2025 summer update reported by a biotech industry newsletter counted 7 total participants at that point, with the trial having recently secured regulatory approval to expand into Canada, the United Kingdom, and the UAE. Press.farm’s more recent coverage identifies specifically three named patients — Noland Arbaugh, Alex, and Brad — using the company’s “Telepathy” software interface as of 2026, alongside broader trial expansion. Taken together, these figures paint a consistent picture: the program has grown steadily from its 2024 start, roughly doubling every several months, while remaining a genuinely small clinical cohort rather than anything approaching commercial scale.
Photo by cottonbro studio via Pexels
The First Patient’s Story
Noland Arbaugh’s case remains the field’s defining reference point. Tech4Impact Summit’s strategic overview describes the moment precisely: in January 2024, the 29-year-old quadriplegic became the first human to receive a Neuralink brain implant, and within weeks was playing chess and video games using only his thoughts. By early 2026, Arbaugh had logged thousands of hours of continuous neural interface use — a detail that matters clinically, since sustained, long-term device reliability is arguably a more important benchmark than any single impressive demonstration. His journey wasn’t without complications: pdpspectra’s detailed BCI overview documents that several of his implanted electrode threads partially retracted from the cortex within weeks of implantation, reducing the number of electrodes capturing usable signal — the field’s first major real-world engineering setback, which Neuralink addressed through software adaptations to extract more signal from the remaining electrodes, and later through firmer anchoring and revised insertion techniques in subsequent patients.
The Manufacturing Shift Musk Announced
Musk’s own words, posted on X and reported by MDDI Online, frame 2026 as a deliberate manufacturing inflection point: “Neuralink will start high-volume production of brain-computer interface devices and move to a streamlined, almost entirely automated surgical procedure in 2026.” He specifically highlighted one surgical change as significant: “device threads will go through the dura, without the need to remove it. This is a big deal.” Basenor’s analysis of the update explains why this specific change matters clinically — previously, accessing the brain’s cortex required cutting through or removing a section of the dura, the tough outer membrane protecting the brain. Allowing threads to pass through without removing the dura represents a meaningful reduction in surgical invasiveness, since it eliminates a step that carries its own separate surgical risk.
Beyond Motor Control: Vision Restoration
Neuralink’s ambitions have expanded beyond restoring cursor and computer control for paralyzed patients. Press.farm’s coverage identifies a newly approved program called “Blindsight,” a vision-restoring device that received what the outlet describes as a “massive new regulatory green light.” 3zebras’ broader industry overview notes Neuralink’s second-generation device, reportedly in development for 2026 trials, specifically addresses the earlier thread-retraction issue with a revised electrode design, while the company works to scale from single-patient milestones toward broader clinical trials.
Photo by MART PRODUCTION via Pexels
Neuralink Isn’t Alone Anymore
3zebras’ industry overview is explicit that the competitive landscape has expanded far beyond Musk’s company since the field’s 2024 clinical debut. Synchron takes a fundamentally different, less invasive approach with its Stentrode device, delivered through blood vessels rather than requiring open-brain surgery, and Synchron is already FDA-cleared, according to Tech4Impact Summit’s overview — a meaningfully different regulatory status than Neuralink’s current research-protocol basis. Other named competitors actively developing BCI technology include Precision Neuroscience’s surface-based Layer 7 device, Onward, and Paradromics, alongside the academic BrainGate consortium, which pioneered much of the foundational research underlying the entire field and has separately demonstrated paralyzed patients controlling robotic arms, typing on screens, and operating wheelchairs through thought alone.
Funding and Market Scale
Neuralink secured an additional $650 million in Series E funding in June 2025, valuing the company at approximately $9 billion at that time, according to Basenor’s reporting. Tech4Impact Summit’s strategic overview places the broader brain-computer interface market at an estimated $8 billion to $12 billion, a range reflecting genuine market-sizing uncertainty in an emerging medical technology category, but nonetheless indicating a field that has moved well past purely academic research funding.
What Hasn’t Happened Yet
It’s worth being direct about the field’s current limits: 3zebras’ overview states plainly that no BCI is commercially available in 2026. Every current implant, from Neuralink or any competitor, operates under a research protocol or an expanded-access program, not as a purchasable medical device available through normal clinical channels. That distinction matters for setting realistic expectations — genuine regulatory approval for broad commercial availability remains a future milestone, not a current reality, even as the clinical trial data continues to accumulate.
Frequently Asked Questions
How many people have received Neuralink implants?
As of the most recent reporting, at least 12 patients had received Neuralink implants as of September 2025, with the trial actively expanding into Canada, the UK, and the UAE.
Is Neuralink’s brain chip available to buy?
No. As of 2026, no brain-computer interface from Neuralink or any competitor is commercially available; all current implants operate under research protocols or expanded-access programs.
What problem did Neuralink’s first patient experience?
Noland Arbaugh, the first Neuralink patient, experienced partial retraction of several implanted electrode threads within weeks of surgery, reducing usable signal, which the company addressed through software adaptations and later through improved surgical techniques.
Who are Neuralink’s main competitors?
Synchron (already FDA-cleared, using a less invasive blood-vessel-based approach), Precision Neuroscience, Onward, Paradromics, and the academic BrainGate consortium are all actively developing competing brain-computer interface technology.
Sources & Methodology
This article draws on reporting from: MDDI Online’s January 2, 2026 coverage of Neuralink’s 2026 production plans and direct quotes from Elon Musk; Basenor’s May 2026 analysis of Neuralink’s 2026 progress and funding history; 3zebras’ June 2026 competitive overview of the brain-computer interface field; Press.farm’s coverage of Neuralink’s 2026 patient progress and the Blindsight regulatory approval; pdpspectra’s May 2026 detailed overview of the BCI patient pathway; Tech4Impact Summit’s March 2026 strategic industry overview; and a biotech industry newsletter’s coverage of Neuralink’s 2025 summer trial update. Figures reflect the most recently published information as of this article’s last-updated date.
This article is for informational purposes and does not constitute medical or investment advice.